Patents by Inventor Knud Erik Andersen
Knud Erik Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8846677Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.Type: GrantFiled: May 15, 2012Date of Patent: September 30, 2014Assignee: High Point Pharmaceuticals, LLCInventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
-
Patent number: 8501739Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.Type: GrantFiled: June 30, 2006Date of Patent: August 6, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
-
Publication number: 20130079340Abstract: Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings, having histamine H3 antagonistic activity can be used in pharmaceutical compositions.Type: ApplicationFiled: October 25, 2012Publication date: March 28, 2013Inventors: Florencio Zaragoza Dorwald, Rolf Hohlweg, Inge Thoger Christensen, Jane Marie Lundbeck, Knud Erik Andersen
-
Patent number: 8394842Abstract: Certain novel benzothiazoles and benzoxazoles, e.g., 2-(piperazin-1-yl)benzothiazoles and 2-(piperazin-1-yl)benzoxazoles, optionally substituted in the 3 and/or 4 positions of the piperazine rings,! of the general formula (1): having histamine H3 antagonistic activity can be used in pharmaceutical compositions.Type: GrantFiled: March 22, 2007Date of Patent: March 12, 2013Assignee: High Point Pharmaceuticals, LLCInventors: Florencio Zaragoza Dorwald, Rolf Hohlweg, Inge Thoger Christensen, Jane Marie Lundbeck, Knud Erik Andersen
-
Publication number: 20120232078Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.Type: ApplicationFiled: May 15, 2012Publication date: September 13, 2012Applicant: HIGH POINT PHARMACEUTICALS, LLCInventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
-
Publication number: 20110009420Abstract: The present invention provides compounds of the formula wherein R1, R2 and B are as herein described, pharmaceutical compositions comprising these compounds, use of these compounds for the preparation of pharmaceutical compositions and methods of use thereof for the treatment and/or prevention of disorders and diseases wherein modulation of the H3 receptor is beneficial.Type: ApplicationFiled: September 16, 2010Publication date: January 13, 2011Applicant: HIGH POINT PHARMACEUTICALS, LLCInventor: Knud Erik Andersen
-
Patent number: 7799924Abstract: A novel class of substituted homopiperidine, piperidine and pyrrolidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor. More particularly, the compounds possess histamine H3 receptor antagonistic activity and are thus useful in the treatment of disorders in which a histamine H3 receptor blockade is beneficial.Type: GrantFiled: December 21, 2007Date of Patent: September 21, 2010Assignee: High Point Pharmaceuticals, LLCInventors: Jan Lindy Sorensen, Knud Erik Andersen, Ingrid Pettersson
-
Publication number: 20090312309Abstract: Novel compounds which interact with the histamine H3 receptor are defined. These compounds are particularly useful in the treatment of a variety of diseases or conditions in which histamine H3 interactions are beneficial. Thus, the compounds may find use, e.g., in the treatment of diseases of the central nervous system, the peripheral nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinological system. The novel compounds have a core consisting of a 6 membered aromatic ring containing at least one nitrogen atom and two carbon atoms in the ring and, at the remaining positions in the ring, there is either a carbon or a nitrogen atom.Type: ApplicationFiled: June 30, 2006Publication date: December 17, 2009Applicant: HIGH POINT PHARMACEUTICALS, LLCInventors: Rolf Hohlweg, Knud Erik Andersen, Jan Lindy Sorensen, Jane Marie Lundbeck
-
Publication number: 20080113968Abstract: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: ApplicationFiled: April 10, 2007Publication date: May 15, 2008Applicant: Novo Nordisk A/SInventors: Florencio Zaragoza Dorwald, Knud Erik Andersen, Jan Lindy Sorensen
-
Patent number: 7332508Abstract: A novel class of substituted homopiperidine, piperidine and pyrrolidine derivatives, methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor. More particularly, the compounds possess histamine H3 receptor antagonistic activity and are thus useful in the treatment of disorders in which a histamine H3 receptor blockade is beneficial.Type: GrantFiled: December 15, 2003Date of Patent: February 19, 2008Assignee: Novo Nordisk A/SInventors: Jan Lindy Sorensen, Knud Erik Andersen, Ingrid Pettersson
-
Patent number: 7208497Abstract: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: GrantFiled: June 27, 2002Date of Patent: April 24, 2007Assignee: Novo Nordisk A/SInventors: Florencio Zaragoza Dorwald, Knud Erik Andersen, Jan Lindy Sørensen
-
Patent number: 6908926Abstract: Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula I wherein R1, R2, R3, R4, R5, R6, A, X, Y and Z are as defined in the specification.Type: GrantFiled: April 12, 2000Date of Patent: June 21, 2005Assignee: Novo Nordisk A/SInventors: Florencio Zaragoza Dörwald, Knud Erik Andersen, Tine Krogh Jørgensen, Bernd Peschke, Birgitte Schjellerup Wulff, Ingrid Pettersson, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Müller, Bernd Krist
-
Patent number: 6756384Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: GrantFiled: July 23, 2002Date of Patent: June 29, 2004Assignees: Novo Nordisk A/S, Boehringer Ingelheim International GmbHInventors: Knud Erik Andersen, Florencio Zaragoza Dorwald, Bernd Peschke, Ulla Grove Sidelmann, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Muller, Bernd Krist, Birgitte Eriksen
-
Publication number: 20040019039Abstract: A novel class of substituted piperazines and diazepanes, pharmaceutical compositions comprising them and use thereof in the treatment of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: ApplicationFiled: June 27, 2002Publication date: January 29, 2004Inventors: Florencio Zaragoza Dorwald, Knud Erik Andersen, Jan Lindy Sorensen
-
Patent number: 6610721Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: GrantFiled: March 16, 2001Date of Patent: August 26, 2003Assignee: Novo Nordisk A/SInventors: Knud Erik Andersen, Florencio Zaragoza Dorwald
-
Publication number: 20030135056Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: ApplicationFiled: July 23, 2002Publication date: July 17, 2003Inventors: Knud Erik Andersen, Florencio Zaragoza Dorwald, Bernd Peschke, Ulla Grove Sidelmann, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Muller, Bernd Krist, Birgitte Eriksen
-
Patent number: 6569849Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula wherein X, Y, Z, A, R1, R2, r and s are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to secretion and circulation of insulin antagonising peptides.Type: GrantFiled: October 3, 1997Date of Patent: May 27, 2003Assignee: Novo Nordisk A/SInventors: Tine Krogh Jorgensen, Rolf Hohlweg, Peter Madsen, Knud Erik Andersen, Svend Treppendahl, Uffe Bang Olsen, Zdenek Polivka, Alexandra Silhankova, Karel Sindelar, Vladimir Valenta, Tomas Kalisz
-
Publication number: 20020151539Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula 1Type: ApplicationFiled: March 14, 2002Publication date: October 17, 2002Inventors: Tine Krogh Jorgensen, Knud Erik Andersen, Rolf Hohlweg, Uffe Bang Olsen, Erik Fischer, Zdenek Polivka, Kaler Sindelar
-
Patent number: 6437147Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.Type: GrantFiled: March 16, 2001Date of Patent: August 20, 2002Assignees: Novo Nordisk, Boehringer Ingelheim International GmbHInventors: Knud Erik Andersen, Florencio Zaragoza Dorwald, Bernd Peschke, Ulla Grove Sidelmann, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Muller, Bernd Krist, Birgitte Eriksen
-
Patent number: 6417218Abstract: A class of substituted imidazole compounds of formula I methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor are disclosed. More particularly, these compounds possess histamine H3 receptor antagonistic activity and are thus useful for the treatment of disorders in which a histamine H3 receptor blockade is beneficial.Type: GrantFiled: January 18, 2000Date of Patent: July 9, 2002Assignees: Novo Nordisk A/S, Boehringer Ingelheim International GmbHInventors: Florencio Zaragoza Dorwald, Knud Erik Andersen